Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Bundle Branch Pacing to Preserve Ejection Fraction in Atrial Fibrillation Trial (BEAT)

6 agosto 2026 aggiornato da: Poitiers University Hospital

Left Bundle Branch Area Pacing Versus Conventional Right Ventricular Pacing as Initial Strategy for Patients With Permanent Atrial Fibrillation and Preserved Left Ventricular Ejection Fraction Requiring Cardiac Pacing: an Open-label, Multicenter, Randomized Clinical Trial. - the BEAT Study -

The goal of this clinical trial is to learn whether left bundle branch area pacing, a technique designed to activate the heart's natural electrical conduction system, is better than conventional right ventricular pacing in adults with permanent atrial fibrillation, preserved heart pumping function, and a need for a pacemaker.

The main questions it aims to answer are:

Does left bundle branch area pacing reduce the risk of death, unplanned hospitalization for heart failure, or the need to replace the initial pacing system with biventricular pacing over 2 years? Does it better preserve heart function and quality of life, without increasing pacemaker-related complications?

Researchers will compare left bundle branch area pacing with conventional right ventricular pacing. A total of 642 participants will be randomly assigned to receive one of these two pacing strategies.

Participants will:

Have a single-chamber pacemaker implanted using either left bundle branch area pacing or conventional right ventricular pacing Undergo electrocardiograms, echocardiograms, and pacemaker checks during 2 years of follow-up Attend follow-up visits approximately 2, 12, and 24 months after implantation Be contacted by telephone approximately 6 and 18 months after implantation Complete questionnaires about their health and quality of life at the beginning and end of the study

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The BEAT Study is a prospective, multicenter, open-label, randomized controlled clinical trial designed to compare left bundle branch area pacing with conventional right ventricular pacing as the initial pacing strategy in adults with permanent atrial fibrillation, preserved left ventricular ejection fraction, and an indication for permanent ventricular pacing.

Conventional right ventricular pacing is the standard pacing strategy for patients with bradycardia. The ventricular lead is usually positioned at the right ventricular apex or septum. Although this approach is well established, prolonged right ventricular pacing produces a non-physiological pattern of ventricular electrical activation. The resulting electrical and mechanical dyssynchrony may progressively impair left ventricular function and lead to pacing-induced cardiomyopathy, heart failure, hospitalization, and the need for a subsequent procedure to upgrade the pacing system to biventricular pacing.

Patients with permanent atrial fibrillation who require a pacemaker may be particularly exposed to these complications because they generally have a high burden of ventricular pacing. This applies both to patients with slow atrial fibrillation and to those undergoing atrioventricular node ablation for rapid atrial fibrillation. Although these patients may have preserved left ventricular systolic function at the time of pacemaker implantation, repeated non-physiological ventricular activation could contribute to subsequent deterioration in cardiac function.

Left bundle branch area pacing is a conduction-system pacing technique in which the ventricular lead is advanced through the interventricular septum to stimulate the left bundle branch or the surrounding conduction tissue. By recruiting the heart's intrinsic conduction system, this approach is intended to produce more physiological and synchronous ventricular activation than conventional right ventricular pacing. It may therefore preserve left ventricular function and reduce the clinical consequences associated with long-term ventricular pacing.

Evidence supporting left bundle branch area pacing has increased, particularly in patients with impaired left ventricular function or an indication for cardiac resynchronization. However, long-term randomized evidence remains limited in patients with permanent atrial fibrillation, preserved left ventricular ejection fraction, and an expected high ventricular pacing burden. In particular, the effect of the initial pacing strategy on major clinical events in this population has not been adequately established.

The study hypothesis is that left bundle branch area pacing, compared with conventional right ventricular pacing, will reduce clinically important adverse events over 2 years by limiting pacing-related ventricular dyssynchrony and preventing deterioration in left ventricular function.

A total of 642 participants will be enrolled and randomly assigned in a 1:1 ratio to one of two pacing strategies:

Left bundle branch area pacing: implantation of a single-chamber pacemaker with the ventricular lead positioned within the left bundle branch area through the interventricular septum to capture the cardiac conduction system.

Conventional right ventricular pacing: implantation of a single-chamber pacemaker with the ventricular lead positioned at the right ventricular apex or right ventricular septum.

Randomization will be stratified by participating center and by the indication for pacing: rapid permanent atrial fibrillation requiring atrioventricular node ablation or slow permanent atrial fibrillation. Because the implantation techniques are different and identifiable to the treating clinicians, the study is open label.

Participants will be followed for 24 months after pacemaker implantation. Study assessments will include clinical evaluation, pacemaker interrogation, 12-lead electrocardiography, echocardiography, collection of hospitalizations and cardiac reinterventions, assessment of adverse events, and evaluation of health-related quality of life. Follow-up will include clinical visits approximately 2, 12, and 24 months after implantation and telephone contacts approximately 6 and 18 months after implantation.

Echocardiography will be performed at baseline and at the end of the 2-year follow-up to evaluate changes in left ventricular systolic function and ventricular volumes. Pacemaker interrogation will be used to document device function and the proportion of ventricular pacing. Quality of life will be assessed using the Short Form-36 Health Survey and the Kansas City Cardiomyopathy Questionnaire.

The principal comparison will assess whether left bundle branch area pacing improves the proportion of participants who remain free from all-cause death, unplanned hospitalization for heart failure, and upgrade to biventricular pacing at 2 years. Additional analyses will examine cardiac function, individual clinical events, cardiac reinterventions, device- and procedure-related complications, and changes in quality of life. Unplanned heart failure hospitalizations and upgrades to biventricular pacing will be reviewed by an independent adjudication committee.

The primary analysis will follow the intention-to-treat principle. The study is intended to determine whether a physiological pacing strategy should replace conventional right ventricular pacing as the preferred initial approach for patients with permanent atrial fibrillation, preserved left ventricular function, and a substantial anticipated requirement for ventricular pacing.

Tipo di studio

Interventistico

Iscrizione (Stimato)

642

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  • Age ≥ 18 years and <90 years
  • Atrial fibrillation requiring ventricular pacing because of

    1. rapid atrial fibrillation requiring atrioventricular node ablation; or
    2. slow atrial fibrillation i.e. ≤ 50 bpm on admission ECG).
  • Left ventricular ejection fraction ≥50%.
  • Affiliated person or beneficiary of the French social security scheme
  • Having given their informed consent.

Exclusion Criteria:

  • Indication for an implantable cardioverter defibrillator.
  • Presence of a mechanical tricuspid valve
  • Any prior attempt at implantation of an implantable cardioverter defibrillator, cardiac resynchronization therapy or LBBA pacing
  • Glomerular filtration rate <40 mL/min/1,73m2 with CKD-EPI formula
  • Chronic respiratory failure
  • Serious medical condition with life expectancy of <2 years
  • Pregnant or breastfeeding women, women of childbearing age who do not have effective contraception (hormonal/mechanical: per os, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy)
  • Persons benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergency situations

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: LBBA pacing
The LBBA pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted in the LBBA of the cardiac conduction system through the interventricular septum.
The LBBA pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted in the LBBA of the cardiac conduction system through the interventricular septum.
Comparatore attivo: Conventional pacing
The conventional pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted either at the apex or the septum of the right ventricle.
The conventional pacing group will be composed of patients randomized to receive a single chamber pacemaker with a ventricular lead implanted either at the apex or the septum of the right ventricle.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of post-implantation adverse events
Lasso di tempo: At two years
proportion of post-implantation adverse events, combining all-cause mortality, unplanned hospitalization related to heart failure, and upgrade to biventricular pacing.
At two years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Left ventricular ejection fraction
Lasso di tempo: At 2 years post-implantation.
Left ventricular ejection fraction assessed with echocardiography
At 2 years post-implantation.
Left ventricular end-systolic volume
Lasso di tempo: At 2 years post-implantation
Left ventricular end-systolic volume assessed with echocardiography
At 2 years post-implantation
Time to composite outcome
Lasso di tempo: Through study completion, an average of 2 years
Time to the first event between death, unplanned hospitalization related to heart failure, and upgrade to biventricular during the 2-year follow-up period
Through study completion, an average of 2 years
Unplanned hospitalization related to heart failure
Lasso di tempo: During the 2-year follow-up perio
Time to unplanned hospitalization for heart failure
During the 2-year follow-up perio
All-cause mortality
Lasso di tempo: During the 2-year follow-up period
Time to all-cause death
During the 2-year follow-up period
Upgrade to biventricular pacing
Lasso di tempo: During the 2-year follow-up period
Time to upgrade to biventricular
During the 2-year follow-up period
Complications
Lasso di tempo: During the 2-year follow-up period
Proportions of pocket hematoma, pneumothorax, lead dislodgment, pacing threshold elevation, pericardial effusion, pocket/wound infection, systemic infection, lead fracture, diaphragmatic stimulation, or pacemaker syndrome
During the 2-year follow-up period
Cardiac reintervention
Lasso di tempo: During the 2-year follow-up period
Time to cardiac reintervention for upgrade to biventricular pacing or due to a complication
During the 2-year follow-up period
Quality of life : Short Form 36 Questionnaire score
Lasso di tempo: Evolution between baseline and 2 years post-implantation
Evolution at the Short Form 36 Questionnaire score. Minimum score: 0; Maximum score: 100; A higher score indicates better health-related quality of life.
Evolution between baseline and 2 years post-implantation
Quality of life : Kansas City Cardiomyopathy Questionnaire score
Lasso di tempo: Evolution between baseline and 2 years post-implantation
Evolution at the Kansas City Cardiomyopathy Questionnaire score. Minimum: 0 - worst possible heart-failure-related health status; Maximum: 100 - best possible health status, with fewer symptoms and limitations
Evolution between baseline and 2 years post-implantation

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 settembre 2026

Completamento primario (Stimato)

14 agosto 2028

Completamento dello studio (Stimato)

14 agosto 2030

Date di iscrizione allo studio

Primo inviato

2 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

6 agosto 2026

Primo Inserito (Effettivo)

12 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 agosto 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 agosto 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • BEAT STUDY

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .